Phase Weeks 1-2 Draw volume 7.5 units (0.075 mL) Total blend delivered ~2.0 mg total blend GHK-Cu ~1.25 mg KPV ~250 mcg BPC-157 ~250 mcg TB-500 ~250 mcg Phase Weeks 3-4 Draw volume 15 units (0.15 mL) Total blend delivered ~4.0 mg total blend GHK-Cu ~2.5 mg KPV ~500 mcg BPC-157 ~500 mcg TB-500 ~500 mcg Phase Weeks 5-8 Draw volume 22.5 units (0.225 mL) Total blend delivered ~6.0 mg total blend GHK-Cu ~3.75 mg KPV ~750 mcg BPC-157 ~750 mcg TB-500 ~750 mcg Phase Weeks 9-12 (taper) Draw volume 15 units (0.15 mL) Total blend delivered ~4.0 mg total blend GHK-Cu ~2.5 mg KPV ~500 mcg BPC-157 ~500 mcg TB-500 ~500 mcg Blend ratio 50 / 10 / 10 / 10 mg GHK-Cu dominant Select a draw volume from the titration table above to see the approximate amount of each peptide delivered
this summary covers the well-studied copper tripeptide GHK-Cu (glycyl-L-histidyl-L-lysineCu)
Why is BPC-157 so cheap online compared to at a medical clinic
Trials have typically used titration periods of about 6 weeks, starting at a lower dose and stepping up to the full maintenance dose
Learn more about this medical solution on Arpovo Health, where expert guidance helps ensure safety
Mechanistically, the peptide perturbs the FOXO4 interaction with p53, which selectively causes p53 nuclear exclusion and cell-intrinsic apoptosis (Figure 2, this novel senolytic did remove cells from the PDL9 chondrocytes, which was accompanied by significantly reduced levels of SA--gal staining